8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  May 8, 2009

Cellu Tissue Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware	333-118829	06-1346495
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
1855 Lockeway Drive Suite 501 Alpharetta, Georgia		30004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code    (678) 393-2651

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.  Regulation FD Disclosure.

From time to time the Company meets with investors to present information relating to the Company’s business.  Certain information that may be used by the Company in such meetings is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits.

The following is being furnished as an exhibit to this Current Report on Form 8-K:

(d) Exhibits

99.1Investor Slides.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cellu Tissue Holdings, Inc.
	(Registrant)
Date: May 8, 2009	By: /s/ David J. Morris
	Mr. David J. Morris
	Senior Vice President, Finance and Chief Financial Officer

3

EXHIBIT INDEX

99.1 Investor Slides.

4

EX-99.1

Exhitbit 99.1

Net sales by current product mix (Q4 breakdown) Note: Converted Tissue includes $7 million of Foam net sales Machine Glazed 21% Converted Tissue 43% Tissue Hard Rolls 36%

$42.2 $75.1 $73.3 $99.6 $207.1 $25.6 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 2009PF Converted tissue net sales—FY ending February ($ millions) CAGR: 51.9% Converted tissue cases sold (000’s) CAGR: 45.9% 14,070 EBITDA/ton 2,128 3,195 5,149 4,934 6,472 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 2009PF Converted Tissue Hard Rolls Machine Glazed

Cellu’s tissue converting capability 2009 CT & AP&F PF Combined Revenue Retail 22% AFH 17% Hardroll/MG 61% Pro forma for 2009, converted tissue products represented 39% of total revenues